Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The emergence across Southeast Asia of strains of malaria that display increasing tolerance to the more commonly used therapies could undo years of progress in battling the disease, and public-private partnerships are trying to respond as quickly as possible

You may also be interested in...

AstraZeneca Sees Malaria Venture Pact As Template For Branching Out Assets Into New Areas

In what it calls a template for future agreements that might further leverage its library of compounds, AstraZeneca has agreed to give Medicines for Malaria Venture a no-charge look at about 500,000 proprietary compounds to see if they have potential in Plasmodium falciparum malaria

Korea's Shin Poong Seeks EMEA Special Approval For Anti-malarial Drug Pyramax

SEOUL - Local South Korean drug maker Shin Poong Pharmaceutical submitted a new drug application to the European Medicines Agency for its new artemisinin combination therapy Pyramax (pyronaridine-artesunate) for malaria

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts